Clinical Trial Update: A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD) [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 study evaluating single-dose and multiple-dose regimens of GBT021601-012 in participants with Sickle Cell Disease; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• GBT021601-012 (GBT021601-012)

Snippet

Sponsor: Pfizer | Conditions: Sickle Cell Disease | Phase 1 | Status: COMPLETED | Results posted: 2024-06-10